On 1 and 2 October 2026, Université Paris-Saclay will host the TOX’26 symposium, organised by Adebiotech under the theme ‘NAMs & NGRA for the Predictive Assessment of Systemic Toxicity’. GenEvolutioN will attend as Gold Sponsor, and our General Manager Gautier Decock will co-chair Session 4, dedicated to the validation and regulatory acceptance of new approach methodologies. An event we have been looking forward to.
TOX’26: what is it?
Adebiotech — a French think tank dedicated to life sciences — has for several years organised high-level symposia at the intersection of science, regulation and industry. TOX’26 continues this tradition by bringing together, over two days, the leading institutional, academic and industrial stakeholders involved in the development of New Approach Methodologies (NAMs) and Next Generation Risk Assessment (NGRA) for systemic toxicity evaluation.
The programme is ambitious: four thematic sessions, flash poster presentations, a multi-sector roundtable (pharma, cosmetics, chemicals, nutrition), and high-level contributions from ANSES, INERIS, the OECD, EFSA, Servier, and the University of Galway, among others. Two full days to take stock of the current state of the art, the regulatory barriers, and the prospects for the real-world adoption of animal-free testing methods.
Why GenEvolutioN is committed as Gold Sponsor
At GenEvolutioN, NAMs are not a forward-looking concept — they are tools we develop, validate and routinely deploy in our laboratories, serving clients across the pharmaceutical, cosmetics, food and chemical industries. Our expertise in in vitro genotoxicity — including the Ames test, in vitro micronucleus assay, RSMN, and phototoxicity testing — is built on alternative methods whose regulatory acceptability lies at the very heart of the TOX’26 debate.
Supporting this event as Gold Sponsor is a way of expressing a deep-seated conviction: the future of toxicological assessment depends on predictive, scientifically robust methods that are recognised by regulatory authorities. It is also our way of actively contributing to a French scientific ecosystem of which we are genuinely proud to be a part.
Gautier Decock co-chairing Session 4
Our General Manager Gautier Decock has been invited to co-chair Session 4, entitled ‘Validation and Regulatory Acceptance’. The session will cover a broad range of topics: cost-benefit analysis applied to NAMs (INERIS), the international validation of a new genotoxicity test (INRAE/Toxalim), Pepper’s work on endocrine disruption assessment methods, the OECD’s validation and regulatory recognition strategy, and the NAM qualification process currently being developed at EFSA level.
In our view, this is the most strategically important session of the symposium. It addresses the central question of how to move from method development to official regulatory recognition — a challenge GenEvolutioN navigates in real time, through its validation projects and ongoing dialogue with competent authorities.
Join us on 1 and 2 October 2026
Whether you are a researcher, a regulatory affairs professional, or an industry representative from pharma, cosmetics or chemicals, TOX’26 is not to be missed. Université Paris-Saclay provides an exceptional setting for two days of high-level scientific exchange.
The GenEvolutioN team will be on site throughout the event. If you would like to discuss your in vitro toxicology needs, our methods, or our areas of expertise, please do not hesitate to get in touch — we would be delighted to arrange a meeting on the sidelines of the symposium.
👉 Full programme and registration: https://asso.adebiotech.org/nams-et-ngra-pour-levaluation-predictive-de-la-toxicite-systemique-tox26/
